Literature DB >> 9484774

Intron-exon structure of the MET gene and cloning of an alternatively-spliced Met isoform reveals frequent exon-skipping of a single large internal exon.

J C Lin1, M Naujokas, H Zhu, S Nolet, M Park.   

Abstract

Hepatocyte growth factor/scatter factor (HGF/SF) is a multifunctional factor that stimulates epithelial cell mitogenesis, motility, invasion, and morphogenesis. Its receptor is encoded by the MET proto-oncogene, a transmembrane receptor tyrosine kinase. Several studies have suggested a role for MET as a dominant oncogene in tumor development and progression. Conversely, MET is located at a region on chromosome 7q31 frequently deleted in carcinomas, suggesting that recessive mutations in MET may exist in certain cancers. To facilitate a search for mutations in MET, we have obtained the intron-exon structure of the human MET gene. We present the genomic structure of the first member of the Met receptor family to be characterized. Interestingly, MET contains a large second exon of 1214 nucleotides. We show that this exon, containing the AUG for the Met receptor, is frequently skipped in normal human tissues and cell lines, and corresponds to a ubiquitously expressed 7 kb Met transcript. This transcript yields no detectable protein product in vivo. Thus, unlike other genes, in which alternative splicing often gives rise to proteins with distinct activities, exon-skipping of MET exon 2 is predicted to decrease the abundance of a Met mRNA encoding a functional Met receptor.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9484774     DOI: 10.1038/sj.onc.1201599

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  6 in total

1.  A novel isoform of met receptor tyrosine kinase blocks hepatocyte growth factor/Met signaling and stimulates skeletal muscle cell differentiation.

Authors:  Minseon Park; Bok-Soon Lee; Soung-Hoo Jeon; Hyun-Ja Nam; Gwang Lee; Chul-Ho Kim; Hyeseong Cho; Jae-Ho Lee
Journal:  J Biol Chem       Date:  2014-12-03       Impact factor: 5.157

Review 2.  Overcoming resistance to targeted therapy using MET inhibitors in solid cancers: evidence from preclinical and clinical studies.

Authors:  Nehad M Ayoub; Dalia R Ibrahim; Amer E Alkhalifa
Journal:  Med Oncol       Date:  2021-10-19       Impact factor: 3.064

3.  Multiplexed, targeted profiling of single-cell proteomes and transcriptomes in a single reaction.

Authors:  Alex S Genshaft; Shuqiang Li; Caroline J Gallant; Spyros Darmanis; Sanjay M Prakadan; Carly G K Ziegler; Martin Lundberg; Simon Fredriksson; Joyce Hong; Aviv Regev; Kenneth J Livak; Ulf Landegren; Alex K Shalek
Journal:  Genome Biol       Date:  2016-09-19       Impact factor: 13.583

4.  Association between miR-199a rs74723057 and MET rs1621 polymorphisms and the risk of hepatocellular carcinoma.

Authors:  Qianqian Wang; Xiangyuan Yu; Qiang Li; Linyuan Qin; Shengkui Tan; Xiaoyun Zeng; Xiaoqiang Qiu; Bo Tang; Junfei Jin; Weijia Liao; Moqin Qiu; Lijun Tan; Gaofeng He; Xiaomei Li; Songqing He; Hongping Yu
Journal:  Oncotarget       Date:  2016-11-29

Review 5.  Pushing the limits of the scanning mechanism for initiation of translation.

Authors:  Marilyn Kozak
Journal:  Gene       Date:  2002-10-16       Impact factor: 3.688

6.  MET and autism susceptibility: family and case-control studies.

Authors:  Inês Sousa; Taane G Clark; Claudio Toma; Kazuhiro Kobayashi; Maja Choma; Richard Holt; Nuala H Sykes; Janine A Lamb; Anthony J Bailey; Agatino Battaglia; Elena Maestrini; Anthony P Monaco
Journal:  Eur J Hum Genet       Date:  2008-11-12       Impact factor: 4.246

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.